TP53 and non-small cell lung carcinoma: However, more than 50% of the KRAS mutated-NSCLC show a concurrent genomic alteration on one or more other genes (mainly, TP53, STK11, KEAP1, CDKN2A, AKT1, PI3KA, BRAF) [89,90,91].